Shin Nippon Biomedical Laboratories, Ltd.

Tokyo Stock Exchange 2395.T

Shin Nippon Biomedical Laboratories, Ltd. EBITDA Margin for the year ending March 31, 2024: 33.95%

Shin Nippon Biomedical Laboratories, Ltd. EBITDA Margin is 33.95% for the year ending March 31, 2024, a -10.18% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Shin Nippon Biomedical Laboratories, Ltd. EBITDA Margin for the year ending March 31, 2023 was 37.80%, a -29.28% change year over year.
Shin Nippon Biomedical Laboratories, Ltd. EBITDA Margin for the year ending March 31, 2022 was 53.45%, a 45.59% change year over year.
Shin Nippon Biomedical Laboratories, Ltd. EBITDA Margin for the year ending March 31, 2021 was 36.72%, a 18.10% change year over year.
Shin Nippon Biomedical Laboratories, Ltd. EBITDA Margin for the year ending March 31, 2020 was 31.09%, a 43.60% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

Tokyo Stock Exchange: 2395.T

Shin Nippon Biomedical Laboratories, Ltd.

CEO	Dr. Ryoichi Nagata F.F.P.M., M.D., Ph.D.
IPO Date	March 8, 2004
Location	Japan
Headquarters	St. Luke’s Tower
Employees	1,451
Sector	Healthcare
Industries Clinical Trials Biotechnology Pharmaceuticals

Description

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, provides drug discovery and development services in Japan and internationally. It offers pre-clinical laboratory services, such as good laboratory practice inspections; general and specific toxicity studies; pathological examinations; PK/PD of biopharmaceuticals, immunotoxicity tests, and antibody production; reproductive and developmental toxicity studies; pharmacology and pharmacological efficacy studies; and imaging services. The company also engages in the establishment and validation of analytical methods, analysis of biological samples, and calculation of pharmacokinetic parameters; and provides absorption, distribution, metabolism, and excretion studies using radioisotope-labeled compounds. In addition, it provides site management organization services for clinical trials; clinical contract research organization services; and translational research services, including research and development of nasal delivery systems, nucleic acid adjuvants, and regenerative medicines. The company was founded in 1957 and is headquartered in Tokyo, Japan.

Key trends

Past 5 years